EHD3 Antibody

What is EHD3 and why is it significant in cellular research?

EHD3 (EH domain containing 3) is a 60.9 kDa protein that plays a critical role in regulating early-endosome-to-Golgi transport pathways. It is also known as PAST3 or PAST homolog 3 and belongs to the EHD family of proteins involved in membrane trafficking. The significance of EHD3 lies in its crucial function in maintaining endosomal sorting and recycling processes. Research has demonstrated that EHD3 depletion impacts sorting in endosomes by altering the kinetics and route of receptor recycling to the plasma membrane. EHD3 is particularly important in regulating transport from early endosomes to the perinuclear recycling endosome, making it a valuable target for studies on intracellular trafficking mechanisms. Its conservation across species including human, mouse, rat, and other mammals further highlights its fundamental importance in cellular biology .

What are the key differences between polyclonal and monoclonal EHD3 antibodies in research applications?

Polyclonal EHD3 antibodies, such as those derived from rabbit hosts, recognize multiple epitopes on the EHD3 protein, providing enhanced signal detection but potentially lower specificity. These antibodies (like catalog #25320-1-AP) offer robust signals in Western blot, immunohistochemistry, and immunofluorescence applications. In contrast, monoclonal EHD3 antibodies (like clone 5C8) recognize single epitopes, offering higher specificity but potentially lower sensitivity. For quantitative applications requiring precise reproducibility, monoclonal antibodies provide consistent lot-to-lot performance. When detecting native protein conformations or conducting co-immunoprecipitation experiments, polyclonal antibodies often perform better due to their recognition of multiple epitopes that remain accessible despite protein folding. For researchers studying EHD3 in the context of membrane trafficking, the choice between polyclonal and monoclonal antibodies should be based on whether the priority is signal strength (polyclonal) or epitope specificity (monoclonal) .

How do I determine the optimal antibody dilution for my EHD3 detection experiments?

Determining the optimal antibody dilution for EHD3 detection requires systematic titration experiments tailored to your specific application. For Western blotting, start with the manufacturer's recommended range (for example, 1:1000-1:8000 for catalog #25320-1-AP) and test multiple dilutions. Prepare a dilution series (e.g., 1:1000, 1:2000, 1:4000, 1:8000) and perform Western blotting on samples with known EHD3 expression. The optimal dilution provides clear specific bands at 61 kDa with minimal background. For immunohistochemistry, begin with a range of 1:50-1:500 as suggested for many EHD3 antibodies. Test each dilution on positive control tissues like lung, which shows strong EHD3 expression. Evaluate signal intensity, background staining, and specificity at each dilution. For flow cytometry and immunofluorescence, similar titration approaches should be employed. Document all optimization steps, including antigen retrieval conditions (such as using Tris-EDTA buffer at pH 9.0 for IHC), blocking reagents, and incubation times to ensure reproducibility across experiments .

What are the recommended protocols for using EHD3 antibodies in Western blotting experiments?

For optimal Western blotting using EHD3 antibodies, begin with sample preparation by lysing cells in RIPA buffer supplemented with protease inhibitors. Load 20-40 μg of protein per lane based on EHD3 abundance in your sample. Perform SDS-PAGE using an 8-10% gel to provide good resolution around the 61 kDa range where EHD3 is expected to migrate. Transfer proteins to a PVDF membrane at 100V for 60-90 minutes using standard transfer buffer. Block the membrane with 5% non-fat dry milk in TBST for 1 hour at room temperature. Incubate with primary EHD3 antibody at dilutions between 1:1000-1:8000 in blocking buffer overnight at 4°C with gentle rocking. After washing with TBST (3 × 10 minutes), apply appropriate HRP-conjugated secondary antibody (typically 1:5000-1:10000) for 1-1.5 hours at room temperature. Following washing steps, develop using ECL reagent and image. For validation, mouse and human samples show a distinct band at 61 kDa. When troubleshooting, ensure adequate blocking and consider antigen retrieval methods if signal is weak. Multiple antibodies target different regions (N-terminal, internal, C-terminal) of EHD3, so choose based on your experimental needs and expected protein modifications .

What is the recommended approach for using EHD3 antibodies in immunohistochemistry of tissue samples?

For immunohistochemistry with EHD3 antibodies, begin with properly fixed (10% neutral buffered formalin) and paraffin-embedded tissue sections cut at 4-5 μm thickness. Deparaffinize sections through xylene and graded ethanol series to water. Critical for EHD3 detection is the antigen retrieval step - use Tris-EDTA buffer (pH 9.0) as the primary recommendation, with citrate buffer (pH 6.0) as an alternative if results are suboptimal. Heat-mediated antigen retrieval should be performed using pressure cooking or microwave methods for 15-20 minutes. Block endogenous peroxidase activity with 3% hydrogen peroxide for 10 minutes, followed by protein blocking with 5% normal serum. Apply primary EHD3 antibody at dilutions between 1:50-1:500 (start with 1:200 as indicated for lung tissue) and incubate overnight at 4°C in a humidified chamber. After washing in PBS, apply HRP-conjugated secondary antibody for 30-60 minutes at room temperature. Develop with DAB substrate and counterstain with hematoxylin. When validating results, mouse lung tissue serves as an excellent positive control, showing distinct EHD3 expression patterns. For multiplex immunohistochemistry to study co-localization with trafficking markers, consider fluorescence-based approaches with sequential antibody application and stripping protocols .

How can siRNA knockdown of EHD3 be validated when studying vesicular trafficking pathways?

Validating EHD3 knockdown in vesicular trafficking studies requires a multifaceted approach combining molecular, biochemical, and cellular techniques. Begin with siRNA transfection using at least two different siRNA sequences targeting EHD3 to control for off-target effects. Optimal knockdown is typically achieved 48-72 hours post-transfection. For molecular validation, perform qRT-PCR to verify reduction in EHD3 mRNA levels (aim for >70% reduction). At the protein level, perform Western blotting using specific EHD3 antibodies to confirm depletion of the 61 kDa band. Importantly, also verify specificity by demonstrating that EHD1 levels remain unaffected, as shown in previous research. For functional validation, perform a transferrin recycling assay: pulse cells with Transferrin-568 (Tf-568) and chase for 8 minutes. In control cells, Tf-568 reaches both recycling endosomes and early endosomes, while in EHD3-depleted cells, Tf-568 accumulates in enlarged peripheral early endosomes and fails to reach the perinuclear recycling compartment. Additionally, examine the distribution of sorting nexin 1 (SNX1), which shows redistribution to enlarged early endosomes upon EHD3 depletion. These combined approaches provide comprehensive validation of EHD3 knockdown effects on trafficking pathways .

What are the effects of EHD3 depletion on Golgi morphology and function, and how can these be experimentally assessed?

EHD3 depletion causes significant alterations in Golgi morphology and selective functional impairments that can be assessed through multiple experimental approaches. Morphologically, EHD3 knockdown results in highly dispersed and fragmented Golgi stacks, detectable by immunofluorescence using antibodies against Golgi markers. To comprehensively analyze this phenotype, stain for markers of different Golgi compartments including GM130 (cis-Golgi), Giantin (medial-Golgi), and TGN46 (trans-Golgi network). Despite fragmentation, these dispersed structures maintain characteristics of cis-, medial-, and trans-Golgi membranes. For functional analysis, examine protein recruitment to Golgi membranes: while Arf1 assembly remains intact upon EHD3 knockdown, the recruitment of AP-1 γ-adaptin is diminished. To assess anterograde transport, perform the temperature-sensitive VSV-G trafficking assay: transfect cells with GFP-VSV-G, incubate at 40°C to accumulate in ER, then shift to 32°C to allow transport. Despite Golgi fragmentation, VSV-G successfully reaches the plasma membrane within 2 hours in both control and EHD3-depleted cells, indicating the ER-to-Golgi and Golgi-to-plasma membrane secretory pathways remain functional. For retrograde transport, analyze Shiga toxin B subunit (STxB) trafficking, which is disrupted upon EHD3 depletion. Additionally, examine mannose 6-phosphate receptor (M6PR) distribution, which shows altered localization, remaining in peripheral structures rather than concentrating in the TGN region .

How do EHD3 and its interaction partners regulate the early endosome-to-Golgi transport pathway?

EHD3 functions in concert with multiple interaction partners to orchestrate early endosome-to-Golgi transport through a complex regulatory network. EHD3 works with rabenosyn-5, a Rab5 effector, to control sorting events at the early endosome. Experimental evidence shows that siRNA knockdown of either EHD3 or rabenosyn-5, produces similar phenotypes: redistribution of sorting nexin 1 (SNX1) to enlarged early endosomes and disruption of Shiga toxin B subunit (STxB) transport to the Golgi. SNX1, a component of the retromer complex, is critical for selecting cargo destined for retrograde transport to the Golgi. Under normal conditions, SNX1 extensively colocalizes with internalized transferrin at both perinuclear and peripheral endosomal structures. Upon EHD3 depletion, this distribution is altered, affecting cargo sorting. The mechanistic relationship between these proteins can be investigated through co-immunoprecipitation experiments using EHD3 antibodies to pull down protein complexes, followed by Western blotting for interaction partners. Additionally, proximity ligation assays can visualize and quantify these interactions in situ. For dynamic studies, live cell imaging with fluorescently tagged proteins reveals the temporal sequence of these interactions during vesicle formation and transport. Through these approaches, researchers can map the regulatory network controlling early endosome-to-Golgi transport and identify additional components of this critical trafficking pathway .

What are common sources of non-specific binding when using EHD3 antibodies, and how can they be minimized?

Non-specific binding with EHD3 antibodies can arise from several sources that require specific mitigation strategies. Cross-reactivity with other EHD family members (EHD1, EHD2, EHD4) is a primary concern due to sequence homology (~70% similarity). To minimize this, select antibodies targeting unique regions of EHD3, particularly those against the N-terminal domain (AA 22-48) or other distinctive epitopes. Validate specificity by comparing reactivity in wild-type versus EHD3-knockout samples or by performing parallel experiments with siRNA-mediated knockdown. Excessive antibody concentration often leads to non-specific binding; perform careful titration experiments starting with the manufacturer's recommended dilution range (such as 1:1000-1:8000 for Western blot or 1:50-1:500 for IHC). Inadequate blocking contributes significantly to background; optimize blocking conditions by testing different blockers (BSA, normal serum, commercial blockers) and extending blocking time to 1-2 hours at room temperature. For tissue samples, endogenous biotin, peroxidase activity, and Fc receptor binding can create artifacts. Address these through specific blocking steps: use avidin/biotin blocking kits for biotin, 3% hydrogen peroxide for peroxidase, and F(ab')2 antibody fragments for Fc receptor concerns. When troubleshooting, always include positive controls (tissues with known EHD3 expression like lung) and negative controls (primary antibody omission, isotype controls) to accurately distinguish specific from non-specific signals .

How can researchers distinguish between specific EHD3 staining and potential cross-reactivity with other EHD family members?

Distinguishing specific EHD3 staining from cross-reactivity with other EHD family members requires a multi-faceted validation approach. First, select antibodies targeting unique regions of EHD3 with minimal sequence homology to EHD1, EHD2, and EHD4. Antibodies against the N-terminal region (AA 22-48) or other distinctive epitopes of EHD3 provide greater specificity than those targeting conserved domains like the EH domain. Perform Western blot analysis with recombinant EHD1-4 proteins in parallel lanes to assess cross-reactivity profiles. A truly specific EHD3 antibody should exclusively detect the 61 kDa EHD3 band without recognizing other family members. Implement genetic approaches by using siRNA knockdown of EHD3 and examining whether the signal is correspondingly reduced. As demonstrated in published research, effective EHD3 siRNA should deplete EHD3 but leave EHD1 expression unaffected, confirming antibody specificity. For immunohistochemistry and immunofluorescence applications, compare staining patterns with the known differential expression profiles of EHD family members across tissues. EHD3 shows distinctive expression in certain tissues like lung, which can serve as reference points. Consider peptide competition assays where pre-incubation of the antibody with the immunizing peptide should abolish specific EHD3 staining but not cross-reactive signals. For definitive validation, utilize tissues or cells from EHD3 knockout models as negative controls to conclusively identify specific versus non-specific staining .

What strategies can be employed to resolve conflicting data when comparing EHD3 localization studies using different antibodies?

When faced with conflicting EHD3 localization data from different antibodies, implement a systematic investigation strategy. First, characterize each antibody's target epitope – antibodies recognizing different domains (N-terminal, C-terminal, internal regions) may yield different results if the protein undergoes post-translational modifications, proteolytic processing, or if certain epitopes are masked in specific subcellular compartments. Compare the fixation and permeabilization protocols used with each antibody; some epitopes are sensitive to particular fixatives (paraformaldehyde versus methanol) or detergents. Validate each antibody's specificity through siRNA knockdown of EHD3 – a specific antibody should show significantly reduced signal intensity in knockdown cells. Perform side-by-side immunofluorescence studies with multiple antibodies on the same sample preparation to directly compare localization patterns. Co-staining with established organelle markers for early endosomes (EEA1), recycling endosomes (Rab11), and Golgi (GM130) helps determine which antibody correctly identifies EHD3 in its known functional locations. For definitive validation, express tagged versions of EHD3 (GFP-EHD3 or FLAG-EHD3) and compare antibody staining with the tag signal. If discrepancies persist, consider that different antibodies might be detecting different pools or conformational states of EHD3. Document all experimental conditions thoroughly to identify variables that might explain different outcomes and perform Western blotting to verify that all antibodies detect the expected 61 kDa band without additional bands that might represent cross-reactivity .

How can proximity labeling techniques be applied to identify novel EHD3 interaction partners in endosomal trafficking?

Proximity labeling techniques offer powerful approaches for identifying novel EHD3 interaction partners within the dynamic context of endosomal trafficking. BioID (proximity-dependent biotin identification) can be implemented by generating EHD3-BirA* fusion constructs, where the promiscuous biotin ligase BirA* is fused to either the N- or C-terminus of EHD3. When expressed in cells and supplied with exogenous biotin, proteins in close proximity to EHD3 become biotinylated. These biotinylated proteins can then be isolated using streptavidin-based affinity purification and identified through mass spectrometry. Alternatively, APEX2 (engineered ascorbate peroxidase) fusion to EHD3 allows for rapid proximity labeling (under 1 minute) with biotin-phenol upon H₂O₂ addition, capturing even transient interactions in endosomal compartments. For spatially-resolved interaction mapping, design constructs targeting EHD3 to specific compartments using additional targeting motifs. Validate newly identified interaction partners through reciprocal co-immunoprecipitation using EHD3 antibodies, and confirm functional relevance through siRNA knockdown experiments examining effects on endosomal morphology and trafficking pathways. Proximity labeling is particularly valuable for identifying weak or transient interactions that may be missed by traditional co-immunoprecipitation, potentially revealing novel components of the machinery regulating early endosome-to-Golgi transport. For higher specificity, consider TurboID or miniTurbo variants that offer improved labeling efficiency with reduced background .

What are the best approaches for quantitative analysis of EHD3 dynamics in live cell imaging experiments?

Quantitative analysis of EHD3 dynamics in live cell imaging requires sophisticated technical approaches and analytical tools. Begin by generating stable cell lines expressing fluorescently-tagged EHD3 (GFP-EHD3 or mCherry-EHD3) at near-endogenous levels to avoid overexpression artifacts. For dual-color imaging, combine with markers for different endosomal compartments (Rab5-mCherry for early endosomes, Rab11-mCherry for recycling endosomes). Perform imaging on a spinning disk confocal microscope with environmental control (37°C, 5% CO₂) at acquisition rates of 1-2 frames/second to capture vesicle dynamics. For photobleaching experiments, implement FRAP (Fluorescence Recovery After Photobleaching) by bleaching GFP-EHD3 in defined regions and measuring fluorescence recovery kinetics to determine protein mobility and residence time on endosomal membranes. For quantitative analysis, employ specialized tracking software (such as TrackMate in Fiji/ImageJ) to follow individual EHD3-positive vesicles, measuring parameters including velocity, displacement, and directionality. Colocalization analysis with endosomal markers can be quantified using Pearson's or Mander's coefficients, while object-based colocalization provides information on the fraction of EHD3 vesicles positive for specific markers. For advanced analysis, implement automated image segmentation to identify and classify different EHD3-positive structures based on morphological parameters. Statistical analysis should compare multiple cells across independent experiments, with careful documentation of cell passage number and expression levels to ensure reproducibility. This comprehensive approach enables detailed characterization of EHD3 dynamics in the context of endosomal trafficking pathways .

How can researchers integrate EHD3 antibody-based detection with high-content screening approaches to identify modulators of endosomal trafficking?

Integrating EHD3 antibody-based detection with high-content screening offers a powerful approach to identify novel modulators of endosomal trafficking. Design an assay utilizing fixed-cell immunofluorescence with optimized EHD3 antibodies (validated for specificity and sensitivity) combined with markers for early endosomes (EEA1), recycling endosomes (Rab11), and Golgi (GM130). Establish a workflow beginning with cell seeding in 96- or 384-well optical plates, followed by compound treatment or siRNA transfection for 24-72 hours. Following fixation and immunostaining, perform automated image acquisition using a high-content imaging system with 20-40× objective magnification. Develop a multiparametric analysis pipeline measuring: (1) EHD3 expression levels, (2) subcellular distribution patterns, (3) endosome size and number, (4) EHD3 colocalization with compartment markers, and (5) Golgi morphology (dispersed versus compact). For validation, include positive controls known to disrupt endosomal trafficking (e.g., Brefeldin A for Golgi disruption) and negative controls (DMSO, non-targeting siRNA). To assess functional consequences, incorporate cargo trafficking assays such as fluorescently-labeled transferrin uptake and recycling, or STxB retrograde transport. Data analysis should employ machine learning approaches to classify phenotypes and identify compounds or genes that mimic EHD3 depletion phenotypes. Follow-up experiments should validate hits through dose-response studies and orthogonal assays to confirm the mechanism of action. This integrated approach enables systematic identification of molecular players and chemical modulators of EHD3-dependent trafficking pathways with potential therapeutic applications in diseases related to endosomal dysfunction .